本帖最后由 老马 于 2013-3-13 13:43 编辑 ; u4 {9 i% r6 C7 Q3 K6 r3 S e& C
) I3 ]) q- I; ~# _( f; q2 e健择（吉西他滨）+顺铂+阿瓦斯汀7 r$ f5 ^' }" p1 L8 h" U1 \/ i6 ~
Gemzar +Cisplatin + Avastin
7 c# v" q2 t1 o) ^" ~http://annonc.oxfordjournals.org/content/21/9/1804.full
. ^! g8 X- |4 G6 U. \* GOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
0 Y2 d' p! W+ Z' B" \! |7 K7 R {Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
, y; T( F# U b. GResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. ' Y/ `6 j" _2 C* u. r% ]
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 411)
+ y8 u% _( j" E; V; M' p; M华为网盘附件：! e2 N$ _- `, h& i; a( ]
【华为网盘】ava.JPG
7 D/ x8 ^' g w: E |
显身卡
